SCHEDULE: Polar Capital Discloses 5.09% Stake in Verastem

Polar Capital Holdings Plc and its affiliates have reported a 5.09% beneficial ownership stake in Verastem, Inc. as of December 31, 2025.

Summary

• Polar Capital Holdings Plc, along with its affiliates Polar Capital LLP and Polar Capital Funds PLC Biotechnology Fund, has filed a Schedule 13G.
• The filing indicates beneficial ownership of 3,398,898.71 shares of Verastem, Inc.'s common stock.
• This ownership represents 5.09% of Verastem's outstanding common stock.
• The reporting persons hold sole voting and sole dispositive power over all beneficially owned shares.
• The percentage of class is calculated based on 66,776,006 shares outstanding, as reported in Verastem's Form 10-Q on November 3, 2025.
• The securities were not acquired for the purpose of changing or influencing the control of Verastem, Inc.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a significant institutional investor has taken a substantial stake, indicating confidence in the company. However, the filing itself is purely a disclosure of ownership and does not contain operational or financial performance details.

Positives

• A significant institutional investor, Polar Capital, has taken a substantial 5.09% stake in Verastem, Inc., potentially signaling confidence in the company's long-term prospects.
• The filing indicates a passive investment, not intended to influence control, which can be viewed positively by current management and other shareholders.

Negatives

• The filing itself does not contain any negative financial or operational information about Verastem, Inc.

Risks

• The filing does not detail specific risks related to Verastem, Inc.'s operations or financial health, as it is a beneficial ownership disclosure.

Future Outlook

This filing does not provide any forward-looking statements or guidance from Verastem, Inc. or the reporting entities regarding the company's future performance or strategic direction.

Industry Context

Verastem, Inc. operates in the biotechnology sector. The disclosure of a significant stake by Polar Capital Funds PLC Biotechnology Fund suggests that a specialized fund focused on the biotech industry sees value in Verastem. This can be a positive signal within the competitive and often volatile biotechnology landscape, indicating a professional assessment of the company's potential.

Comparison to Industry Standards

• A 5.09% stake is a notable position for an institutional investor, often triggering reporting requirements and indicating a conviction in the investment.
• While specific comparable companies or projects are not mentioned in this filing, the investment by a dedicated biotechnology fund suggests that Verastem's profile aligns with the fund's investment criteria, which typically involves evaluating clinical pipelines, market potential, and management teams against industry peers.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may instill confidence and potentially attract further institutional interest, which could positively impact share price and liquidity.
• Management: The passive nature of the investment (not seeking control) suggests that Polar Capital is comfortable with the current management and strategic direction.

Key Dates

Keywords

Verastem, Polar Capital, Biotechnology Fund, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Equity Stake